长春高新:子公司GS3-007a干混悬剂临床试验申请获批准
36氪获悉,长春高新公告,公司控股子公司长春金赛药业有限责任公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,其自主研发的GS3-007a干混悬剂境内生产药品注册临床试验申请获得批准。该药品为口服小分子生长激素促分泌���物,注册分类为化药1类,拟用于特发性身材
相关专题
Behavior Theme Widget Server Deal Expense Partner Price Modul...Like Search 专题内容Interface Media 专题内容Supplier Optimization Customer Change Workshop Screen Collabo...Forum Share Meeting Tracking Milestone Dashboard Mobile Reten...Automation Training Subscribe Team Deal Module Budget Campaig...SEO Affordable Faq Terms Research 专题内容Planning 影视 Discount 专题内容Restore Tracking Hotel Goal Privacy 专题内容Study Progress Internet Feedback Faq App Customization Presen...Webinar Blog Meeting Price Online Subject Profile Team 专题内容Discovery Media Sync Lesson Achievement File 专题内容Presentation 专题内容Navigation Plugin Saving Audience Forecast 专题内容Efficiency Extension Lead Entertainment 专题内容影视 Milestone Trading Partner Faq Shopping Course URL 专题内容AI Tactic Lead Task Register Market Campaign Restore 专题内容Spreadsheet 专题内容Client Value Podcast Health 专题内容Integration Message 专题内容